OBJECTIVE: The aim of this study was to compare the cost and effectiveness of a minimally invasive (MI) versus traditional sternotomy (ST) approach for mitral valve surgery (MVS). METHODS: From January 1, 2003, to December 31, 2008, a total of 847 patients underwent isolated MVS at our institution. Propensity matching on 22 clinical variables was carried out to generate a study cohort of 434 patients (217 matched pairs). Direct and indirect costs from the hospital perspective were retrospectively obtained from our finance department. Total hospital costs were further stratified into 13 standardized institutional billing categories. In addition, data on morbidity, mortality, discharge location, hospital readmissions within 1 year, and freedom from reoperation were obtained. RESULTS: Compared with ST, MIMVS was associated with a $9054 ± $3302 lower mean total hospital cost (P = .006), driven largely by a reduction in direct (P = .003) versus indirect costs (P = .06). Among the 13 billing categories, MIMVS was associated with a significant reduction in costs of cardiac imaging (P = .004), laboratory tests (P = .005), boarding and nursing (P = .001), and radiology (P = .002). More patients in the ST group required intubation for more than 72 hours (P = .019); however, there were no differences in morbidity or long-term survival (P = .334). A higher proportion of MI patients were discharged home with no nursing services (P = .018), and a higher proportion of ST patients required readmission within 1 year (P = .023). There were no differences in freedom from reoperation between groups (P = .574). CONCLUSIONS: With equivalent efficacy across a range of measures and lower costs compared with ST, MIMVS represents a cost-saving strategy for MVS.
OBJECTIVE: The aim of this study was to compare the cost and effectiveness of a minimally invasive (MI) versus traditional sternotomy (ST) approach for mitral valve surgery (MVS). METHODS: From January 1, 2003, to December 31, 2008, a total of 847 patients underwent isolated MVS at our institution. Propensity matching on 22 clinical variables was carried out to generate a study cohort of 434 patients (217 matched pairs). Direct and indirect costs from the hospital perspective were retrospectively obtained from our finance department. Total hospital costs were further stratified into 13 standardized institutional billing categories. In addition, data on morbidity, mortality, discharge location, hospital readmissions within 1 year, and freedom from reoperation were obtained. RESULTS: Compared with ST, MIMVS was associated with a $9054 ± $3302 lower mean total hospital cost (P = .006), driven largely by a reduction in direct (P = .003) versus indirect costs (P = .06). Among the 13 billing categories, MIMVS was associated with a significant reduction in costs of cardiac imaging (P = .004), laboratory tests (P = .005), boarding and nursing (P = .001), and radiology (P = .002). More patients in the ST group required intubation for more than 72 hours (P = .019); however, there were no differences in morbidity or long-term survival (P = .334). A higher proportion of MI patients were discharged home with no nursing services (P = .018), and a higher proportion of ST patients required readmission within 1 year (P = .023). There were no differences in freedom from reoperation between groups (P = .574). CONCLUSIONS: With equivalent efficacy across a range of measures and lower costs compared with ST, MIMVS represents a cost-saving strategy for MVS.
Authors: Tomislav Mihaljevic; Lawrence H Cohn; Daniel Unic; Sary F Aranki; Gregory S Couper; John G Byrne Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: W R Chitwood; J R Elbeery; W H Chapman; J M Moran; R L Lust; W A Wooden; D H Deaton Journal: J Thorac Cardiovasc Surg Date: 1997-02 Impact factor: 5.209
Authors: Jeffrey A Morgan; Barbara A Thornton; Joy C Peacock; Karen W Hollingsworth; Craig R Smith; Mehmet C Oz; Michael Argenziano Journal: J Card Surg Date: 2005 May-Jun Impact factor: 1.620
Authors: James P Greelish; Lawrence H Cohn; Marzia Leacche; Michael Mitchell; Alexandros Karavas; John Fox; John G Byrne; Sary F Aranki; Gregory S Couper Journal: J Thorac Cardiovasc Surg Date: 2003-08 Impact factor: 5.209
Authors: Robert B Hawkins; J Hunter Mehaffey; Samuel M Kessel; Jolian J Dahl; Irving L Kron; John A Kern; Leora T Yarboro; Gorav Ailawadi Journal: J Thorac Cardiovasc Surg Date: 2018-04-03 Impact factor: 5.209
Authors: Andrew B Goldstone; Pavan Atluri; Wilson Y Szeto; Alen Trubelja; Jessica L Howard; John W MacArthur; Craig Newcomb; Joseph P Donnelly; Dale M Kobrin; Mary A Sheridan; Christiana Powers; Robert C Gorman; Joseph H Gorman; Alberto Pochettino; Joseph E Bavaria; Michael A Acker; W Clark Hargrove; Y Joseph Woo Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209